(Reuters) – Merck said on Friday its drug Keytruda, in combination with chemoradiotherapy, met the main goal in a late-stage study in newly diagnosed patients with high-risk locally advanced cervical cancer.
(Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
Comments